Approval · Notice of Compliance 19952 · 2017
ZYKADIA: Notice of Compliance 19952
Issued October 20, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
Issued with conditions (NOC/c): the company must confirm the benefit in further studies.
- Notice number
- 19952
- Date
- October 20, 2017
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Final report for study cldk378bx2101 as per the commitment in the letter of undertaking (lou) dated march 20, 2015
- With conditions
- Yes (NOC/c)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ZYKADIA | Not yet assigned | — |
Medicinal ingredients
- CERITINIB 150 MG per CAP